Pluristem's PLX Cells Have Potential to Treat ARS. Vertex Rheumatoid Arthritis Drug Meets Study Goals. Print E-mail
By Staff and Wire Reports   
Wednesday, 07 September 2011 20:17
Below is a look at some of the headlines for companies that made news in the healthcare sector on September 7, 2011.

Pluristem Therapeutics Inc.  (NASDAQ:PSTI) announced that animal studies it has conducted suggest that its PLacental eXpanded (PLX) cells are potentially effective in treating life threatening hematopoietic complications associated with Acute Radiation Syndrome (ARS).

Animals were exposed to lethal doses of radiation and on the following day injected intravenously with either PLX cells or a placebo containing no cells. Nine days following treatment with the PLX cells, the animals' bone marrow and spleen were examined for signs of hematopoietic (blood forming) tissue. On day 23, bone marrow and blood samples were examined in the surviving animals.

Overall survival and body weight changes were also monitored. Highlights of the study include; An up to four-fold increase in the survival rate accompanied by a corresponding weight regain was seen in irradiated animals treated with PLX cells, versus those treated with the placebo; Preliminary differential blood analysis on days 21-23 showed an increase in red cell count, the hemoglobin and hematocrit levels and the total number of myeloid cells in the surviving animals treated with PLX cells; The spleens of the animals treated with PLX cells had an elevated number of hematopoietic colonies on day 9, in comparison to those treated with the placebo.

---

Vertex Pharmaceuticals, Inc.  (NASDAQ:VRTX) experimental oral drug for rheumatoid arthritis met the main goals of a mid stage study. Vertex's VX-509 significantly reduced signs and symptoms of the painful condition and disease activity at the two highest of four tested doses compared with a placebo after 12 weeks of treatment, according to results of the 204-patient mid-stage trial released on Tuesday.

The company, which in May launched its first commercial product the hepatitis C treatment Incivek plans to evaluate VX-509 in a six-month mid-stage study based on results of the 12 week trial.



Also Wednesday:



Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceuticals company innovating abuse deterrent drugs, today announced the Company will participate in the 2011 Stifel Nicolaus Healthcare Conference at The Four Seasons Boston.

Alkermes, Inc. (NASDAQ: ALKS)
announced today that its corporate presentation will be webcast live from the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2011, at 10:20 a.m. ET.

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that company management will participate at the Baird 2011 Healthcare Conference on September 8 at 11:00 am ET in New York City.

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present the latest data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Lisbon, Portugal, September 12-16.

Dendreon Corporation (NASDAQ:DNDN) today announced that management will host a conference call on Thursday, September 8, 2011 at 4:30 p.m. ET to provide a structural and business update on the company.

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that the company will be participating in the Rodman & Renshaw 13th Annual Global Investment Conference being held at the Waldorf-Astoria Hotel in New York City from September 11th – 13th.

Endo Pharmaceuticals (Nasdaq: ENDP) today announced that Alan Levin, executive vice president and chief financial officer will present a corporate overview at the UBS Global Life Sciences Conference on Wednesday, September 21, 2011 at 10:30 a.m. ET.

Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT)
announced today that Mark Fletcher, the Company's President & Chief Executive Officer, and Dr. Eric von Hofe, President of the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com) will make a Generex/Antigen presentation at  the Rodman & Renshaw 13th Annual Healthcare Conference.

Lannett Company, Inc. (NYSE AMEX: LCI) today reported financial results for the fiscal 2011 fourth quarter and full year ended June 30, 2011.

Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced that Glen de Vries, president; Bruce Dalziel, chief financial officer; and Cory Douglas, senior vice president, controller, will present at the Stifel Nicolaus Healthcare Conference at 9:45 a.m. ET on September 9, 2011 in Boston, MA.

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative diagnostic products, today announced that it received positive scientific advice late last week from the European Medicines Agency (EMA) on the development of RIGScanTM CR, the Company’s proprietary radiopharmaceutical for the detection of colorectal cancer.

RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) announced today that the Company will be participating in the Rodman & Renshaw 13th Annual Global Investment Conference being held at the Waldorf-Astoria Hotel in New York City from September 11th – 13th. J.J. Finkelstein, RegeneRx’s president and chief executive officer, will deliver the Company’s corporate presentation on Tuesday, September 13th, at 2:00 p.m. (Eastern Time).

Taro Pharmaceutical Industries Ltd. (“Taro,” Pink Sheets: TAROF) announced today that Mr. Hasmukh Shah has resigned from Taro's Board of Directors (“Board”), effective August 22, 2011, due to personal reasons and the vacancy has been filled by the appointment of Professor Dov Pekelman, who will serve until Taro’s next Annual General Meeting of Shareholders.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter